Loading
A phase 1/2 trial of OBX-115 in melanoma and non-small-cell lung cancer, run by Obsidian Therapeutics, Inc., now recruiting.
Safety and Efficacy of OBX-115 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06060613 by Obsidian Therapeutics, Inc., with 208 participants planned, started 2023-10-25 and due to reach its primary completion in 2029-06-30. Interventions recorded: OBX-115.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/